Simulation of the impact of atropisomer interconversion on plasma exposure of atropisomers of an endothelin receptor antagonist

Journal of Clinical Pharmacology

Volumn 44, Issue 7, 2004, Pages 680-688

  Zhou, Yuji Simon ^a   Tay, L K ^a   Hughes, D ^a   Donahue, S ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Atropisomer; BMS 207940; Clinical inversion; Drug development; Enantiomers; Pharmacokinetics; Simulation

Indexed keywords

BMS 207940; ENDOTHELIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; ATROPISOMER; COMPARTMENT MODEL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CONFORMATION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG POTENCY; HUMAN; HUMAN CELL; ISOMER; ISOMERISM; RACEMIC MIXTURE; RECEPTOR BLOCKING; ROOM TEMPERATURE;

ADMINISTRATION, ORAL; AREA UNDER CURVE; CRYSTALLOGRAPHY, X-RAY; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; OXAZOLES; RECEPTORS, ENDOTHELIN; STEREOISOMERISM; SULFONAMIDES;

EID: 2942679602     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004266622     Document Type: Article

References (13)

1. Srinivas NR, Barbhaiya RH, Midha KK: Enantiomeric drug development: issues, considerations, and regulatory requirements. J Pharm Sci 2001;90(9):1205-1215.
2. Department of Health and Human Services, Food and Drug Administration: FDA's Policy Statement for the Development of New Stereo-isomeric Drugs. Washington, DC: Department of Health and Human Services, 1992.
3. Committee for Proprietary Medicinal Products, Working Parties on Quality and Efficacy of Medicinal Products: Note for Guidance: Investigation of Chiral Active Substances. London: European Agency for the Evaluation of Medicinal Products, 1993.
4. Daniels JM, Nestmann ER, Kerr A: Development of stereoisomeric (chiral) drugs: a brief review of scientific and regulatory considerations. Drug Info J 1997;31:639-646.
5. Tan SC, Hutt AJ: Drug chirality and its clinical significance. Drugs 1996;52(Suppl. 5):1-12.
6. Nation RL: Chirality in new drug development: clinical pharmacokinetic considerations. Clin Pharmacokinet 1994;27(4):249-255.
7. Baillie TA, Adams Wj, Kaiser DG, Olanoff LS, Halstead GW, Harpootlian H, et al: Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans. J Pharmacol Exp Ther 1989; 249(2);517-523.
8. Smith DE, Paliwal JK, CoxSr, Berardi RR, Dunn-Kucharski VA, Elta GH: The effect of competitive and non-linear plasma protein binding on the stereoselective disposition and metabolic inversion of ibuprofen in healthy subjects. Biopharm Drug Dispos 1994;15(7): 545-561.
9. Eriksson T, Björkman S, Roth B, Fyge A, Höghmd P: The enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality 1998;10(3): 223-228.
10. Reist M, Roy-de Vos M, Montseny J-P, Mayer JM, Carrupt P-A, Berger Y, et al: Very slow chiral inversion of clopidogrel in rats: a pharmacokinetic and mechanistic investigation. Drug Metab Dispos 2000;28(12):1405-1410.
11. Eriksson T, Bjorkman S, Hoglund P: Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 2001;57(5):365-376.
12. Eriksson T, Björkman S, Roth B, Hìglund P: Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J Pharm Pharmacol 2000;52(7):807-817.
13. Eriksson T, Björkman S, Roth B, Fyge A, Höglund P; Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 1995;7(1):44-52.